Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice

Metabolic Brain Disease

Volumn 23, Issue 2, 2008, Pages 147-154

  Kadoguchi, Naoto ^a   Kimoto, Hiroki ^a   Yano, Ryohei ^a   Kato, Hiroyuki ^b   Araki, Tsutomu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Dopamine system; Mice; Parkinson's disease; Proteasome; Western blot analysis

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; ACTIN; AROMATIC AMINE; CARBOBENZOXYBUTYLGLUTAMYLALANYLLEUCINAL; DOPAMINE; PROTEASOME INHIBITOR; TYROSINE 3 MONOOXYGENASE; VANILLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; WESTERN BLOTTING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CORPUS STRIATUM; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; HOMOVANILLIC ACID; MALE; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEURONS; NEUROTOXINS; OLIGOPEPTIDES; PARKINSONIAN DISORDERS; PROTEASOME ENDOPEPTIDASE COMPLEX; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; MUS;

EID: 44449113069     PISSN: 08857490     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11011-008-9082-9     Document Type: Article

References (28)

1. Araki T, Kumagai T, Tanaka K, Matsubara M, Kato H, Itoyama Y, Imai Y (2001) Neuroprotective effect of riluzole in MPTP-treated mice. Brain Res 918:176-181
2. Bove J, Zhou C, Jackson-Lewis V, Taylor J, Chu Y, Rideout HJ, Wu DC, Kordower JH, Petrucelli L, Przedbroski S (2006) Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 60:260-264
3. Camacho-Arroyo I, Villamar-Cruz O, Gonzalez-Arenas A, Guerra-Araiza C (2002) Participation of the 26S proteasome in the regulation of progesterone receptor concentrations in the rat brain. Neuroendocrinology 76:267-271
4. Fenteany G, Schreiber SL (1998) Latacystin, proteasome function, and cell fate. J Biol Chem 273:8545-8548
5. Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Busceti CL, Ruffoli R, Soldani P, Ruggieri S, Alessandri MG, Paparelli A (2003) Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci 23:8955-8966
6. Inden M, Kondo J, Kitamura Y, Takata K, Nishimura K, Taniguchi T, Sawada H, Shimohama S (2005) Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkisonian rats. J Pharmacol Sci 97:203-211
7. Jana NR, Dikshit P, Goswami A, Nukina N (2004) Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem 279:11680-11685
8. Kazi A, Urbizu DA, Kuhn DJ, Acebo AL, Jackson ER, Greenfelder GP, Kumar NB, Dou QP (2003) A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells. Int J Mol Med 12:879-887
9. Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8:739-758
10. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608
11. Koguchi Y, Kohno J, Nishio M, Takahashi K, Okuda T, Ohnuki T, Komatsubara S (2000) TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities. J Antibiot 53:105-109
12. Kordower JH, Kanaan NM, Chu Y, Suresh Babu RS, Stansell J, Terpstra BT, Sortwell CE, Strece-Collier K, Collier TJ (2006) Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol 60:264-268
13. Kurosaki R, Muramatsu Y, Kato H, Watanabe Y, Imai Y, Itoyama Y, Araki T (2005) Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice. Eur Neuropsychopharmacol 15:57-67
14. McNaught KS, Olanow CW (2003) Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol 53:S73-S86
15. McNaught KS, Olanow CW (2006) Proteasome inhibitor-induced model of Parkinson's disease. Ann Neurol 60:243-247
16. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P (2001) Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2:589-594
17. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179:38-46
18. McNaught KS, Perl DP, Brownell AL, Olanow CW (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56:149-162
19. Miwa H, Kubo T, Suzuki A, Nishi K, Kondo T (2005) Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition. Neurosci Lett 380:93-98
20. Nam S, Smith DM, Dou QP (2001) Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276:13322-13330
21. Petrucelli L, Dawson TM (2004) Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann Med 36:315-320
22. Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC (2000) Proteasome inhibitor PS519 reduces infarction and attenuates leukocytes infiltration in rat model of focal cerebral ischemia. Stroke 31:1686-1693
23. Schapira AH, Cleeter MW, Muddle JR, Workman JM, Cooper JM, King RH (2006) Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol 60:253-255
24. Sherman MY, Goldberg AL (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29:15-32
25. Sin N, Kim KB, Elofsson M, Meng L, Auth H, Kwok BH, Crews CM (1999) Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett 9:2283-2288
26. van Leyen K, Siddiq A, Ratan RR, Lo EH (2005) Proteasome inhibition protects HT22 neuronal cells from oxidative glutamate toxicity. J Neurochem 92:824-830
27. Yamamoto N, Sawada H, Izumi Y, Kume T, Katsuki H, Shimohama S, Akaike A (2007) Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress. J Biol Chem 282:4364-4372
28. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM (2000) Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 97:13354-13359